Oxandrolone vs Tesamorelin
Well Studied vs FDA Approved
synergistic Mechanism-based · 47% Oxandrolone and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Oxandrolone Tesamorelin
Weight 306.44 Da 5,135.9 Da
Half-life ~9-10 hours 26-38 minutes
Chain — 44 amino acids
Type 17-alpha-alkylated anabolic-androgenic steroid (C19H30O3) GHRH analog
Key Benefits
Oxandrolone
01 Promotes lean muscle mass gains with minimal water retention
02 Supports recovery of lost body weight following surgery, trauma, or chronic illness
03 Reduces bone pain associated with osteoporosis and improves bone mineral density
04 Does not aromatize to estrogen, avoiding estrogen-related side effects
05 Well-studied safety profile in women, children, and burn patients
06 Enhances nitrogen retention and protein synthesis during caloric deficit
07 Attenuates glucocorticoid-induced catabolism in post-surgical and burn patients
08 Lower androgenic potency compared to most oral anabolic steroids
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
Oxandrolone
20-50 mg/day (male), 5-20 mg/day (female) / Split into 2 doses daily (morning and evening)
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
Oxandrolone
HDL cholesterol suppression (dose-dependent, most significant lipid effect)
LDL cholesterol elevation
Mild hepatic stress (elevated liver enzymes ALT/AST)
Suppression of endogenous testosterone production
Mild headaches
Nausea or gastrointestinal discomfort
Changes in libido (increase or decrease depending on hormonal context)
Oily skin and mild acne
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Known or suspected prostate cancer
Breast cancer in males
Breast cancer with hypercalcemia in females
Pregnancy (Category X - known to cause fetal harm)
Nephrosis or nephrotic phase of nephritis
Hypercalcemia
Severe hepatic dysfunction or active liver disease
Hypersensitivity to oxandrolone or any formulation component
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
Oxandrolone Tesamorelin
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest September 2023 June 2025
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.